Tizianel, I. http://orcid.org/0000-0003-4092-5107
Detomas, M. http://orcid.org/0000-0003-1490-5575
Deutschbein, T. http://orcid.org/0000-0003-0586-0168
Fassnacht, M. http://orcid.org/0000-0001-6170-6398
Albiger, N. http://orcid.org/0000-0002-0646-4362
Iacobone, M. http://orcid.org/0000-0002-6057-4642
Scaroni, C. http://orcid.org/0000-0001-9396-3815
Ceccato, F. http://orcid.org/0000-0003-1456-8716
Funding for this research was provided by:
Università degli Studi di Padova
Article History
Received: 2 June 2023
Accepted: 17 September 2023
First Online: 5 October 2023
Declarations
:
: All authors have no conflicts of interest for this topic that might be perceived as influencing the impartiality of the reported research. Filippo Ceccato: PhD grant by Novartis Pharma, Lecture fees by HRA Pharma. Timo Deutschbein: personal honorary for Advisory Boards (HRA Pharma, Recordati Rare Diseases).
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Comitato Etico per la Sperimentazione Clinica, Prot. 0042129 of 2023) and with the Helsinki Declaration Of 1964 and later versions.
: Informed consent was obtained from all patients for being included in the study.